Stroth U, Unger T
Department of Pharmacology, Christian Albrechts University, Kiel, Germany.
J Cardiovasc Pharmacol. 1999;33 Suppl 1:S21-8; discussion S41-3. doi: 10.1097/00005344-199900001-00005.
The renin-angiotensin system (RAS) plays an important role in blood pressure control and in water and salt homeostasis. It is involved in the pathophysiology of hypertension and structural alterations of the vasculature, kidney, and heart, including neointima formation, nephrosclerosis, postinfarction remodeling, and cardiac left ventricular hypertrophy (LVH). Recently, an increased knowledge of the effector peptides of the RAS, their receptors, and their respective functions has led to a new principle of treatment for hypertension: the inhibition of angiotensin (Ang) II via angiotensin-converting enzyme inhibitors or Ang II-receptor antagonists. In this review, the Ang receptors AT1 and AT2 and the potential roles of shorter angiotensin fragments, including Ang III(2-8), Ang IV(3-8), and Ang(1-7), are discussed.
肾素-血管紧张素系统（RAS）在血压控制以及水盐平衡中发挥着重要作用。它参与高血压的病理生理学过程以及血管、肾脏和心脏的结构改变，包括新生内膜形成、肾硬化、梗死后重塑和心脏左心室肥厚（LVH）。最近，对RAS效应肽、其受体及其各自功能的深入了解导致了高血压治疗的新原则：通过血管紧张素转换酶抑制剂或血管紧张素II受体拮抗剂抑制血管紧张素（Ang）II。在本综述中，将讨论血管紧张素受体AT1和AT2以及较短血管紧张素片段（包括Ang III(2 - 8)、Ang IV(3 - 8)和Ang(1 - 7)）的潜在作用。
